Journals / Retina-Vitreus / 2011 / Cilt: 19 - Sayı: 1

Our first experience with pascal grid laser photocoagulation in diabetic macular edema

Diyabetik maküla ödeminde pascal grid lazer fotokoagülasyonu ile ilk tecrübelerimiz

Pages
22–26
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The efficacy of the treatment seems to be closely related with the metabolic control

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To assess the efficacy and safety of patterned scan (Pascal) grid laser teratment in diffuse diabetic macular edema.
📊
Key Findings & Data:Materials and Methods: Our study included 30 eyes of 25 patients with diffuse macular edema who were never treated before at our institution.
💡
Conclusion & Impact:The efficacy of the treatment seems to be closely related with the metabolic control
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To assess the efficacy and safety of patterned scan (Pascal) grid laser teratment in diffuse diabetic macular edema. Materials and Methods: Our study included 30 eyes of 25 patients with diffuse macular edema who were never treated before at our institution. All patients had detailed ophthalmologic examination at baseline and at 1, 3 and 6 months after treatment. Best corrected visual acuity (BCVA) was measured using Snellen chart and then converted to logMAR for statistical analysis. Macular thickness (MT) measurements were performed using spectral domain optical cohorence tomography at baseline and at every visit thereafter. Treatment was performed with Pascal system by using its specific grid pattern. Laser parameters and complications were recorded. Results: The mean age of the patients was 57.8±5.6 years. BCVA was 0.63±0.38 (logMAR) at baseline and 0.68±0.47 at 1 month, 0.64±0.47 at 3 months and 0.66±0.47 at 6 months after the treatment. MT was 370±164 μm at baseline and 383±180 μm at 1 month, 374±191 μm at 3 months and 356±196 μm at 6 months after the treatment. There was no statistically significant difference in BCVA and MT before and after the treatment in all visits. There was no complications recorded. Conclusion: Grid photocoagulation by the Pascal system is found to be safe in diffuse diabetic macular edema in short term follow up. BCVA and MT were maintained in all patients at the end of follow up. The efficacy of the treatment seems to be closely related with the metabolic control

Özet

Amaç: Patern taramalı lazer fotokoagulatör (Pascal); önceden belirlenmiş bir paterne göre atış yapabilen ve 10-30 ms gibi kısa atış süreleri kullanan yeni nesil bir fotokoagulatördür. Çalışmamızda diffüz maküler ödemi olan tip 2 diyabet hastalarında Pascal fotokoagülatör kullanılarak uygulanan grid lazer tedavisinin etkinliğinin ve güvenilirliğinin belirlenmesi amaçlandı. Gereç ve Yöntem: Çalışmaya kliniğimiz retina birimine başvuran, daha önce hiç tedavi almamış, diffüz maküler ödemli 25 hastanın 30 gözü dahil edildi. Hastaların tedavi öncesi ve tedavi sonrası 1., 3. ve 6. aylarda tam göz muayeneleri yapıldı. Muayenelerde Snellen eşeli ile en iyi düzeltilmiş görme keskinlikleri alındı ve istatistiksel analiz için logMAR’a çevrildi. Maküla kalınlıkları spektral optik koherens tomografi (OKT) ile tedavi öncesi ve tedavi sonrası her vizite ölçüldü. Topikal anesteziden sonra Pascal fotokoagulatör ile cihaza spesifik grid paterni kullanılarak tedavi uygulandı. Lazer parametreleri ve komplikasyonlar kaydedildi. Bulgular: Çalışmaya alınan hastaların yaş dağılımı 47-72 arasında ve yaş ortalaması 57.8±5.6 idi. Lazer uygulaması öncesi ortalama en iyi düzeltilmiş görme keskinlikleri (logMAR ile) 0.63±0.38 iken, lazer sonrası 1. ayda 0.68±0.47, 3. ayda 0.64±0.47, 6. ayda 0.66±0.47 olarak ölçüldü. Hastaların ortalama görme keskinlikleri arasında istatistiksel anlamlı fark izlenmedi. OKT ile ölçülen maküla kalınlıkları (MK) tedavi öncesi 370±164 μm iken, 1. ayda 383±180 μm, 3. ayda 374±191 μm, 6. ayda 356±196 μm olarak ölçüldü. Ortalama MK arasında istatiksel anlamlı fark izlenmedi. Lazer uygulamasına bağlı komplikasyon izlenmedi. Sonuç: Kısa dönem takiplerde, diffüz diyabetik maküla ödeminde Pascal lazer grid fotokoagülasyonu güvenilir olarak değerlendirildi. Hastaların görme keskinlikleri ve MK ele alındığında mevcut durumun korunabildiği görüldü. Tedavi etkinliğinin metabolik kontrolle yakından ilintili olduğu düşünüldü.

🔖

Cite This Article

KAYIKÇIOĞLU, Ö., SEYMENOĞLU, G., ZERDECİ, N. (2011). Our first experience with pascal grid laser photocoagulation in diabetic macular edema. Retina-Vitreus, Cilt: 19 - Sayı: 1, 22–26. https://ajindex.com/articles/307730

References (15)

  1. Bresnick GH.: Diabetic macular edema. Ophthalmology. 1986;93:989-997
  2. Early Treatment Diabetic Retinopathy Study Group: ETDRS Report No: 1. Photocoagulation for diabetic macular edema. Arch Ophthalmol. 1985;103:1796-1806
  3. Stefansson E.: The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalol Scan. 2001;79:435-440
  4. Aiello LP, Avery RL, Arrigg PG, et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Eng J Med. 1994;331:1519-1520
  5. Gelişken Ö, Kaderli B.: Diabetik maküla ödeminde laser fotokoagülasyon tedavisi. Ret-Vit. 2004;12:1-6
  6. Jain A, Blumenkranz MS, Paulus Y, et al.: Effect of pulse duration on size and character of the lesion in retinal photocoagulation. Arch Ophthalmol. 2008;126:78-85
  7. Blumenkranz MS, Yellachich D, Andersen DA, et al.: Semiautomated patterned scanning laser for retinal photocoagulatiom. Retina. 2006;26:370-376
  8. Nonaka A, Kiryu J, Tsujikawa A, et al.: Inflammatory response after scatter laser photocoagulation in nonphotocoagulated retina. Invest Ophthalmol Vis Sci. 2002;43:1204-1209
  9. Schatz H, Madeira D, McDonald HR, et al.: Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol. 1991;109:1549-1551
  10. Hudson C, Flanagan JG, Turner GS, et al.: Influence of laser photocoagulation for clinically significant macular oedema on short-wawelength and conventional automated perimetry. Diabetologica. 1998;41:1283-1292
  11. Muqit MMK, Gray JCB, Marcellino GR, et al.: Fundus autofluorescence and Fourier- domain optical cohorence tomography imaging of 10 and 20 ms Pascal retinal photocoagulation treatment. Br J Ophthalmol. 2008;93:518-525
  12. Muqit MMK, Sanghvi C, McLauchlan R, et al.: Study of clinical applications and safety for Pascal laser photocoagulation in retinal vascular disorders. Acta Ophthalmol. 2010:16
  13. Modi D, Chiranand P, Akduman L.: Efficacy of patterned scan laser in treatment of macular edema and retinal neovascularization. Clin Ophthalmol. 2009;3:465-470
  14. Sanghvi C, McLauchlan R, Delgado C, et al.: Initial experience with the Pascal photocoagulator: a pilot study of 75 procedures. Br J Ophthalmol. 2008;92:1061-1064
  15. Muqit MM, Gray JC, Marcellino GR, Henson DB, et al.: Barely visible 10-millisecond pascal laser photocoagulation for diabetic macular edema: observations